Last reviewed · How we verify
NCT04583852
Evaluate the Efficacy and Safety of Brightening Micro-needle Patch on Facial Solar Lentigines
NA trial testing AIVÍA, Ultra-Brightening Spot Micro-needle Patch in Solar Lentigines in 35 participants. Completed in 25 January 2021.
8 January 2021
Quick facts
| Lead sponsor | Panion & BF Biotech Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 14 September 2020 |
| Primary completion | 8 January 2021 |
| Estimated completion | 25 January 2021 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- AIVÍA, Ultra-Brightening Spot Micro-needle Patch
- Placebo Micro-needle Patch
Conditions studied
- Solar Lentigines — all drugs for Solar Lentigines →
Sponsor
Panion & BF Biotech Inc.
Who can join
Adults 30 to 65, any sex, with Solar Lentigines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, randomized, double-blind and placebo controlled clinical study to evaluate the efficacy and safety of brightening microneedle patch on facial solar lentigines. Subjects who are 30 to 65-year-old with solar lentigines on their faces will receive brightening microneedle patches on facial solar lentigines once a day for 4 weeks. Afterwards, facial images and skin detectors will be used to analysis their skin, according to various skin tone indexes and skin response score sheets.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment.
Qu F, Geng R, Liu Y, Zhu J. · · 2022 · cited 162× · PMID 35547773 · DOI 10.7150/thno.69999 -
From mechanism to applications: Advanced microneedles for clinical medicine.
Yang Y, Sun H, Sun X, Wang Y, et al · · 2025 · cited 9× · PMID 40463395 · DOI 10.1016/j.bioactmat.2025.04.025
Verify or expand the search:
- PubMed search for NCT04583852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Panion & BF Biotech Inc. trials
Trials by the same sponsor.
- NCT04543812 — PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD · Phase 3 · completed
- NCT03984760 — Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis · Phase 3 · completed
- NCT03256838 — Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04583852 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Panion & BF Biotech Inc.
- Last refreshed: 24 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04583852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing